In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in ...
Aug 18, 2020
0
1
(HealthDay)—Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy, ...
Jul 22, 2020
0
0
Melanoma is a malignant tumour resulting from the transformation of melanocytes, the cells in the skin that undertake to synthesise melanin, a complex polymer which protects us from the negative effects of solar radiation. ...
May 27, 2020
0
1
Patients with advanced melanoma have been able to live longer because of several newly approved targeted treatment options, including BRAF and MEK inhibitors. However, patients will often have different responses to the same ...
Oct 8, 2019
0
17
Based on scientific findings of the Netherlands Cancer Institute, a new combination treatment has been developed for patients with metastatic bowel cancer and a mutation in the BRAF gene. After a clinical trial in over 600 ...
Sep 30, 2019
0
4
One in two patients with metastatic melanoma is alive with combination immunotherapy, according to late breaking results of the CheckMate 067 trial presented at the ESMO Congress 2019 in Barcelona, Spain.
Sep 28, 2019
0
10
Patients with metastatic colorectal cancer harboring a subset of non-V600 mutations in the BRAF gene, known as class 3 BRAF mutations, were more likely to respond to anti-EGFR treatment.
Sep 12, 2019
0
4
New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer. Results of the BEACON CRC Phase III trial have shown that triple therapy targeting ...
Jul 6, 2019
0
0
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase ...
Jul 6, 2019
0
2
The protein BRAF is a key player in the development of many different types of cancer, including melanoma. Scientists have known that BRAF becomes activated by growth factors and subsequently stimulates downstream proteins ...
Apr 24, 2019
0
8
